Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
AbbVie, ADAPTIR, Additonally, addressing, AIA, automatic, BCA, birth, CIADM, deficit, disciplined, distracting, ESPP, exam, exceeded, expenditure, frame, funning, halt, Hematology, immunomodulatory, inadequacy, incorrect, Janury, Kramer, lapse, leakage, malfeasance, malfunction, MD, misappropriation, monospecific, nonexclusive, outage, PAHPA, postponed, quadrennial, reconsider, reevaluated, refocused, repurchase, repurchased, reside, Robert, sabotage, scenario, secrecy, SEER, sequestration, showed, stronger, succeeded, surge, Taxpayer, temporarily, trend, unproductive, unspecified, vital
Removed:
activating, adolescent, advancement, aggressive, alleging, alter, aluminum, amikacin, Ankara, annum, appeal, applied, Army, attain, awaiting, Bacille, bear, biannual, biomedica, borrowing, botulinum, bruising, cancelled, Cangene, capreomycin, caption, cautionary, cellular, characterized, chosen, clarify, closed, collecting, collectively, conserved, contracted, Convention, counterpart, de, deal, dealing, debar, decided, demonstrating, depreciated, derecognition, detected, die, digit, disabling, emergence, employer, encountered, erythema, escalating, ethical, exclusively, exploring, extremely, favor, feasible, fluoroquinolone, foregoing, forgivable, forgiven, Foundation, fourth, Gambia, Genome, Harsanyi, hindered, HIV, humoral, hydroxide, impede, importation, importing, improving, inducing, industrial, infant, infringed, ingredient, injectable, insure, interacting, interpretation, intradermal, intravenously, investigating, isolated, isoniazid, itching, Japan, kanamycin, kill, knowledge, lawsuit, leased, licensee, lineage, lymphocyte, magnitude, mammalian, memory, mid, Ministry, mixture, mortality, muscle, MVA, mycobacterial, narrowly, necessity, Nomination, nonprovisional, optimize, oral, originally, outlicense, pain, passive, pathogen, permanently, placebo, poorly, Postal, pox, predetermined, predominantly, prepare, promissory, realization, recalled, recommending, reinvestment, renovating, requested, responded, rest, rifampicin, route, routine, satisfactorily, scaling, shorter, simultaneously, smallpox, solicited, soliciting, standing, stimulate, StMUG, strong, substantiate, succeed, sued, suggesting, suitability, symptomatic, tangible, termed, threatening, toxic, traditional, train, TroVax, uncured, underserved, unvested, vaccinia, Valortim, vector, wait, warmth, weakened, whichever, white, writing, Zsolt
Filing tables
Filing exhibits
Related press release
EBS similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statement (Form S-8 No. 333-139190) pertaining to the Employee Stock Option Plan, as amended and restated, the 2006 Stock Incentive Plan and individual director options agreements of Emergent BioSolutions Inc., |
(2) | Registration Statement (Form S-8 No. 333-161154) pertaining to the Employee Stock Option Plan, as amended and restated, and the 2006 Stock Incentive Plan of Emergent BioSolutions, Inc., |
(3) | Registration Statement (Form S-4 No. 333-169351) of Emergent BioSolutions Inc. and Subsidiaries, |
(4) | Registration Statement (Form S-3 No. 333-181133) of Emergent BioSolutions Inc. and |
(5) | Registration Statement (Form S-8 No. 333-184699) pertaining to the 2012 Employee Stock Option Plan and the Second Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan. |
of our reports dated March 8, 2013, with respect to the consolidated financial statements of Emergent BioSolutions Inc. and the effectiveness of internal control over financial reporting of Emergent BioSolutions Inc. included in this Annual Report (Form 10-K) of Emergent BioSolutions Inc. for the year ended December 31, 2012.
/s/ Ernst & Young LLP
McLean, Virginia
March 8, 2013